MOA video on the principle of proprietary technology for BreyeTx

Danegaptide uniquely treats the underlying pathology in patients with diabetic retinopathy, stabilizes intercellular communication, and strengthens both the retina's inner and outer blood barriers, which decreases vascular leakage and protection of capillary structures and helps remove the subretinal fluid.
Oral danegaptide therapy for these clinically proven conditions has the potential to be a more effective and less burdensome oral therapy for patients with diabetic retinopathy.

The Goal

"To develop a 3D animation to communicate the mechanism of action of the drug and the process of treating the pathology."

"We had a good iterative design process with the team from Nanobot. They were responsive to our input on biological processes and found good solutions for the design. I am very pleased with the result."